Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel
LON:GSK

GSK Q3 Earnings Report

GSK logo
GBX 1,851.50 +3.50 (+0.19%)
As of 12:03 PM Eastern
ProfileEarnings HistoryForecast

GSK EPS Results

Actual EPS
GBX 49.70
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GSK Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GSK Announcement Details

Quarter
Q3
Date
10/30/2024
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GSK Earnings Headlines

GSK plc (LON:GSK) Receives GBX 2,048.57 Average Price Target from Analysts
August 16 at 3:16 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30963733
Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
August 13, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/could-gsk-plc-gsks-pipeline-acceleration-unlock-a-new-growth-era-1805439/
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.tc pixel
August 17 at 1:00 AM  |  Chaikin Analytics (Ad)
GSK Discloses Executive Notional ADS Acquisition by U.S. President
August 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/gsk-discloses-executive-notional-ads-acquisition-by-u-s-president-2?utm_source=marketbeat.com&utm_medium=referral
GSK AI deal puts biological data first
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/technology/artificial-intelligence/gsk-ai-deal-puts-biological-data-first/vi-AA29sCkc
Deutsche Bank Aktiengesellschaft Reaffirms Hold Rating for GSK (LON:GSK)
August 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30943288
See More GSK Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GSK? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GSK and other key companies, straight to your email.

About GSK

GSK (LON:GSK), together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development, as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

View GSK Profile
Earnings Tools